Aeterna Zentaris (AEZS) Announces $10 Million Bought Deal Offering of Common Shares

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 6,896,552 common shares of Aeterna, at a price to the public of $1.45 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 19, 2021, subject to satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

Aeterna also has granted to the underwriter a 30-day option to purchase up to 1,034,482 additional common shares at the public offering price, less underwriting discounts and commissions.

You May Also Be Interested In

• AbbVie (ABBV): New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary and All Secondary Endpoints
• ImmunityBio (IBRX) Announces Positive OS Results of Anktiva Combined With Checkpoint Inhibitors in NSLC
• Biogen (BIIB) PT Lowered to $300 at H.C. Wainwright